Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice
- 953 Downloads
Exendin-4 is now considered as a promising drug for the treatment of cerebral ischemia. To determine the neuroprotective effects of intranasal exendin-4, C57BL/6J mice were intranasally administered with exendin-4 daily for 7 days before middle cerebral artery occlusion (MCAO) surgery. Intranasally administered exendin-4 produced higher brain concentrations and lower plasma concentrations when compared to identical doses administered interperitoneally. Neurological deficits and volume of infarcted lesions were analyzed 24 h after ischemia. Intranasal administration of exendin-4 exhibited significant neuroprotection in C57BL/6 mice subjected to MCAO by reducing neurological deficit scores and infarct volume. The neuroprotective effects of exendin-4 were blocked by the knockdown of GLP-1R with shRNA. However, exendin-4 has no impact on glucose and insulin levels which indicated that the neuroprotective effect was mediated by the activation of GLP-1R in the brain. Exendin-4 intranasal administration restored the balance between pro- and anti-apoptotic proteins and decreased the expression of Caspase-3. The anti-apoptotic effect was mediated by the cAMP/PKA and PI3K/Akt pathway. These findings provided evidence that exendin-4 intranasal administration exerted a neuroprotective effect mediated by an anti-apoptotic mechanism in MCAO mice and protected neurons against ischemic injury through the GLP-1R pathway in the brain. Intranasal delivery of exendin-4 might be a promising strategy for the treatment of ischemic stroke.
KEY WORDScerebral ischemia exendin-4 intranasal delivery neuroprotection
Stroke is the second leading cause of death worldwide in people aged 60 years or older (1). In addition, stroke is a leading cause of long-term severe disability (2). About 87% of all strokes are represented by ischemic strokes, when the blood flow to the brain is blocked (2). So far, the only drug used for the treatment of acute ischemic stroke approved by the US Food and Drug Administration (FDA) is tissue plasminogen activator (tPA) (3), which is intravenously administered to dissolve blood clots and restore blood flow. However, this thrombolytic therapy has a limited time window for treatment, and it is associated with risks of intracerebral hemorrhage particularly in patients having large-volume lesions (4,5).
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone which plays important roles in blood glucose control and is also considered as a neuropeptide synthesized by neuronal cells. Glucagon-like peptide-1 receptor (GLP-1R) was found to be widely expressed in the brain (6), and its activation protects against neurological disease (7). Exendin-4 is a long-lasting GLP-1R agonist which is widely used for the treatment of type 2 diabetes. The prolonged duration of its action and high apparent in vivo potency make exendin-4 more suitable as a potential pharmacological candidate. Besides its anti-diabetic effects, previous studies have shown that exendin-4 mediated neuroprotection in animal models of stroke (8, 9, 10, 11, 12, 13). Intracerebroventricular injection of exendin-4 was found to exert neuroprotective effect against ischemic stroke in rats with middle cerebral artery occlusion (MCAO) surgery (8). Repeated administration of exendin-4 for 7 days was reported to reduce the infarct volume caused by MCAO in rats (10). Intravenous administration of exendin-4 provided neuroprotection against ischemic injury in mice at 1 h after MCAO, but the effect was lost at 3 h after MCAO (12). Moreover, in both young healthy and aged diabetic/obese mice, exendin-4 showed a neuroprotection against stroke induced by MCAO (9). Therefore, exendin-4 is considered to be a promising strategy for the treatment of cerebral ischemia. However, the blood-brain barrier blocks most small molecules and nearly all large molecules from reaching the diseased brain; thus, systemic delivery of therapeutic peptides are often found to be ineffective (14,15). Peptidic drugs need to be administered at large doses to achieve therapeutic levels in the brain, which would increase the systemic adverse effects. Although peptidic drugs can be directly injected into the brain via intracerebroventricular administration, this invasive technique is not suitable for clinical use (8,16,17). Hence, a noninvasive approach to bypass the blood-brain barrier to target the brain should be worthwhile.
Intranasal administration is more convenient to the patient, and it alleviates the pain and discomfort associated with injections (18). In addition, this route has the potential to overcome the blood-brain barrier and reduce the side effects caused by systemic injection. Thus, this delivery system represents a novel alternative for the treatment of neurologic diseases (19,20). Moreover, intranasal administration has the advantage of avoiding the gastrointestinal and hepatic metabolism (21,22). The nasal cavity has a large surface area and nasal mucosa is highly vascularized; thus, the concentrations of neuroprotective peptides in the brain after intranasal administration are often higher than those observed by systemic injection (23). Furthermore, intranasal administration facilitates self-medication, thereby improving patient compliance compared with injections. Therefore, the intranasal route has aroused increasing interest as a route of administration for peptides. In the present study, we investigated the protective effects of intranasal administration of exendin-4 on cerebral ischemia in MCAO mice and characterized the therapeutic potential of exendin-4 through intranasal delivery for the treatment of cerebral ischemia.
MATERIALS AND METHODS
Male C57BL/6 mice from the Experimental Animal Center of Fourth Military Medical University weighing between 18 and 22 g were used in our study. All protocols were approved by the Animal Care and Use Committee of the Fourth Military Medical University. Every effort was made to minimize the number of animals used and their discomfort. Mice were randomly divided into the following seven groups (n = 12 for each group): group 1, sham group; group 2, intraperitoneally administered (i.p.) vehicle; group 3, 0.5 μg/kg exendin-4 i.p.; group 4, 5.0 μg/kg exendin-4 i.p.; group 5, intranasal (i.n.) administration of vehicle; group 6, 0.5 μg/kg exendin-4 i.n.; group 6, 5.0 μg/kg exendin-4 i.n.. The drug was administered once a day for seven consecutive days. After the last administration, mice in groups 2–6 were subjected to MCAO surgery. Neurological deficits and volume of infarcted lesions were analyzed 24 h after ischemia.
Mice were anesthetized by 1% pentobarbital sodium (10 mg/kg intraperitoneal). After placing them on their backs, a total volume of 20 μl exendin-4 or vehicle per mouse was administered through the nasal cavity. Alternating drops (1 μl/drop) were administered between the left and right nares at the rate of 2 min per drop. To ensure that the drops were naturally inhaled into the nasal cavity, the opposite naris and mouth of the mice were kept closed during the administration.
Determination of Blood Glucose and Plasma Insulin Levels
Blood samples were collected at 0 and 30 min after intranasal administration of exendin-4. The plasma insulin level was determined using an ELISA kit (Millipore, Billerica, MA, USA). The blood glucose level was determined using a glucometer (Roche Diagnostics, Mannheim, Germany).
Determination of Exendin-4 Levels in the Brain and Plasma
The MCAO Model
The MCAO model was performed according to a previously published protocol (24). Briefly, mice were anesthetized with 1% pentobarbital sodium. After the right common carotid artery (CCA) and the external carotid artery (ECA) were isolated, a nylon filament coated with silicon resin was gently advanced approximately 11 mm from the incision near the ECA-CCA branch. Then, the middle cerebral artery (MCA) was occluded. Reperfusion process was performed at 90 min after ischemia. The sham group underwent similar procedure, but the filament was just advanced for 5 mm. The animals were placed on a heating pad on a surgical table soon after the anesthesia. During the entire surgical procedure, the body temperature was continuously monitored with a rectal probe and maintained at 37.0 ± 0.5°C. Mice were kept in heated cages for the next 2 h ischemia, and rectal temperature was frequently measured. Next, the animals were placed in their home cages and allowed free access to food and water.
Evaluation of Neurological Deficits
Neurological deficit scores were analyzed according to Bederson’s score 24 h after MCAO injury, which were defined as follows. No deficit observed corresponded to 0 point; flexion of the contralateral torso and forelimb corresponded to 1 point; decreased resistance to lateral push without circling corresponded to 2 points; leaning towards the affected side corresponded to 3 points; no spontaneous locomotor activity corresponded to 4 points. Higher neurological deficit scores indicated more severe impairment of motor injury.
Calculation of Infarcted Volume by 2-, 3-, 5-Triphenyltetrazolium Chloride (TTC) Staining
Infarcted volume was analyzed by TTC staining after the evaluation of neurological deficit scores (25). The whole brain was removed and placed at −20°C for 30 min. Two-mm slices were cut and incubated in 1.5% TTC solution for 30 min at 37°C in the dark. Next, the slices were fixed in 4% paraformaldehyde for 24 h and digitally scanned. Infarct volume was calculated as the volume of the contralateral hemisphere minus the non-infarcted volume of the ipsilateral hemisphere using PhotoShop CS4 software and shown as the percentage of volume of the contralateral hemisphere.
Knockdown of GLP-1R by Intracerebroventricular Infusion of shRNA
The specific shRNA sequence targeting to the GLP-1R mRNA (GenBank accession no. NM_021332.2, nucleotides 608–628) was constructed into the pGV118 lentiviral vector (GeneChem Co., Ltd., Shanghai, China). High purity (>1.9 ratio 260/280 Abs) transfection ready vector DNA was prepared and resuspended in TE (pH 8.0). The shRNA target sequence was GCCCTCAAGTGGATGTATAGC (5′ to 3′). A scrambled shRNA sequence TTCTCCGAACGTGTCACGT (5′ to 3′) was chosen as a negative control. The lentivirus was intracerebroventricularly injected in the mice brain 7 days before intranasal administration of exendin-4. After anesthesia with 1% pentobarbital sodium, mice were placed in a stereotaxic frame with a mouse head holder. Lentivirus was stereotaxically injected into the right lateral ventricle at the coordinate of bregma −0.4 mm, dorsoventral 0.7 mm, lateral 1.8 mm via a burr hole. The needle was kept in the ventricle for 5 min, and then, it was withdrawn at the rate of 1 mm per minute. After the bone wound was closed with bone wax, the mice were placed back into their cages after their recovery from anesthesia.
After neurological evaluation, the brains were removed and perfused with cold 4% paraformaldehyde. Brain blocks containing hippocampus and prefrontal cortex were cut into frozen section. Coronal sections at the thickness of 10 μm were cut using a Leica CM1800 Cryostat (Leica Microsystems) and then stained with 0.1% cresyl violet for 20 min. The sections were evaluated using light microscopy (Olympus BX60).
Brain sample was harvested from the ischemic penumbra region on the operated side at 24 h after reperfusion. An equal amount of protein (10 μg) was loaded into each lane and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 200 V for 45 min. Protein bands were transferred into polyvinyl difluoride membranes at 100 V for 2 h. Membranes were incubated overnight with a rabbit anti-p-AKT antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), p-CREB (1:1000; Santa Cruz), GLP-1R (1:1000; Santa Cruz), and β-actin (1:5000; Sigma) at 4°C followed by goat anti-rabbit IgG secondary antibody (1:10000; Santa Cruz) for 1 h. Then, the bands on the film were scanned and analyzed.
Statistical analysis was performed using SPSS 13.0. All data, except for neurological scores, were expressed as mean ± SD, and differences between groups were analyzed by one-way ANOVA followed by Dunnett T test. The neurological scores were analyzed using the Kruskal-Wallis test followed by the Mann-Whitney U test with the Bonferroni correction. A value of p < 0.05 was considered statistically significant.
Exendin-4 Accumulated in the Brain After Intranasal Administration
Exendin-4 was intranasally or intraperitoneally administered at the dose of 0.5 or 5.0 μg/kg in C57BL/6 mice. The concentration of exendin-4 was detected in the ischemic penumbra area and plasma at different time points after injection. At 15 min, 0.5 h, 1 h, 1.5 h, and 2 h after administration, the concentration of exendin-4 in the ischemic penumbra area after its intranasal administration at a dose of 0.5 μg/kg was equivalent to the concentration reached after its intraperitoneal administration at a dose of 5 μg/kg. Exendin-4 reached the peak level in the ischemic penumbra area 30 min after intranasal administration, and then, it slowly decreased (Fig. 1a). Brain exendin-4 was still detectable 2 h after i.n. administration of 5.0 μg/kg. In contrast, the plasma level was barely detectable after two i.n. doses of exendin-4 (Fig. 1b). The uptake and distribution of exendin-4 by different brain regions after intranasal or intraperitoneal injection was further explored. The concentration of exendin-4 into the olfactory bulb after intranasal administration was significantly higher than other brain tissue (Fig. 1c), while no significant difference in exendin-4 level was found in the whole brain after intraperitoneal injection (Fig. 1d). To further analyze the transport mechanism after intranasal administration, colchicine, a microtubule assembly inhibitor which can reduce axonal transport (26), was intranasally administered 15 min before intranasal administration of exendin-4. A very low concentration of exendin-4 was detected in the ischemic penumbra area after administration of colchicine (Fig. 1e). These data showed a rapid accumulation of exendin-4 in the brain after intranasal administration and demonstrated that the anterograde axonal transport is essential for this delivery process.
Intranasal Administration of Exendin-4 Improved Functional Outcome and Reduced Infarction Size Caused by MCAO
Neuroprotective Effect of Intranasal Administration of Exendin-4 Was Independent of the Periphery Effect
Intranasal Administration of Exendin-4 Exerted Neuroprotective Effect Against Cerebral Ischemia by Activating the GLP-1R in the Brain
Intranasal Administration of Exendin-4 Activated GLP-1R Signaling Pathway
Intranasal Administration of Exendin-4 Inhibited Neuronal Apoptosis Induced by MCAO
Exendin-4 is in clinical use for the treatment of diabetes and several studies indicate that it may be useful in the treatment of ischemic stroke (8, 9, 10, 11, 12, 13), but there is no study to evaluate the effect of intranasal administration of exendin-4 on cerebral ischemia. We therefore conducted experiments to determine the neuroprotective effects of intranasal administration of exendin-4 on cerebral ischemia in MCAO mice.
Intranasal administration is a useful method of delivering therapeutic peptides to the brain for the treatment of central nervous system (CNS) diseases. After intranasal administration, the peptide uptake by the brain is 5–10 times higher than systemic administration (23). Moreover, peptides delivered by the intranasal route often have a longer permanence time in the brain than those delivered by systemic injection (33), which is in accordance with our research. Intranasal delivery is noninvasive and allows large molecules that do not cross the blood-brain barrier access to the brain. Therapeutic peptides are directly targeted to the CNS with intranasal administration, potentially reducing peripheral exposure and thus unwanted systemic side effects.
In our current study, intranasal administration of exendin-4 at the dose of 0.5 μg/kg exerted neuroprotective effect by reducing neurological deficit scores and infarct volume. However, intraperitoneal administration with the dose of 0.5 μg/kg did not reduce ischemic damage. Although a study (9) demonstrated a significant neuroprotective effect of exendin-4 with lower dose (0.2 μg/kg), it has to be noted that mice received the first administration of exendin-4 at the far higher dose of 5 or 50 μg/kg after MCAO, and then, the treatment continued for 7 days with lower dose of the drug (0.2 μg/kg). The results showed neuroprotective efficacy of 50 μg/kg exendin-4 at 1.5 and 3 h after stroke, but the 5 μg/kg dose was neuroprotective at 1.5 h only. The most efficacious dose of exendin-4 in their study was a bolus of 50 μg/kg followed by continued injections of 0.2 μg/kg. Decreasing the first bolus injection from 50 to 5 μg/kg resulted in diminished efficacy. Therefore, the discrepancy between our research and study by Darsalia et al. are likely due to the different methods of administration.
Previous studies indicated that intranasally administered therapeutics reach the brain via the two main direct pathways, the olfactory and the trigeminal neural pathways. Direct delivery of drugs from the nose to the brain is initially attributed to the olfactory pathway (34, 35, 36). After intranasal administration, peptidic agents usually accumulate in the olfactory bulbs of the brain at the highest concentration and are then distributed throughout the rest of the brain (37,38). Therefore, the olfactory neural pathway is likely one of the largest contributors to intranasal drug delivery. Our data indicated that entry of exendin-4 into the olfactory bulb after intranasal administration was significantly higher than other brain tissue and suggested the olfactory pathway seems to play a pronounced role.
There are two possible mechanisms for the molecule to reach the brain though the olfactory nerve pathways, the extracellular and the intracellular mechanisms. The extracellular transportation is a rapid process which is permitted to occur only few minutes within olfactory cells (39). In contrast, the intracellular transport mechanism is a slow process and lasts for over several hours by axonal transportation (40). Our data indicated that exendin-4 accumulated in the brain 30 min after intranasal administration, then decreased slowly and lasted for 2 h after administration. Previous study published values for fast (5.4 mm/h) and slow (1.5 mm/h) axonal transport of horseradish peroxidase in olfactory nerves and calculated it would take 0.74 h (fast)–2.7 h (slow) for intracellular transport within olfactory neurons to the olfactory bulb (41). From the perspective of axonal transport, this range of speeds is compatible with both retrograde (4–8 mm/h) and fast anterograde transport (2.1–16.6 mm/h) (42,43). In our present study, the time for intranasal exendin-4 to reach the brain was close to the time of the fast axonal transport in olfactory nerves. Because transportation relies on microtubules, depolymerization of those microtubules by colchicine caused some vesicles to target the basolateral surface. Colchicine was used in previous studies to inhibit microtubule assembly and reduces axonal transport (40,43, 44, 45, 46). We next blocked the axonal transport of olfactory by colchicine to examine the possibility that exendin-4 may be transported by an axonal transport system in olfactory neural pathways. Our data showed that administration of colchicine significantly decreased the brain concentration of exendin-4 to a low level. Such an effect is consistent with previous report by Guardia et al. that a very low concentration of aTf was detected in the olfactory bulb when colchicine was administered before the intranasal administration of aTf (40). Based on our results, we speculated that exendin-4 could be transported via fast anterograde axonal transport and intracellular transport mechanisms may play a critical part in this process.
Neuroprotective strategies aimed at decreasing brain damage after ischemic stroke have failed to be translated into the clinical setting along the past decades (47). Up to now, tPA is still the only approved pharmacological treatment for ischemic stroke. Although most of the current therapies are focused on posttreatment after cerebral ischemia, accumulating lines of evidence have demonstrated the efficacy of pretreatment therapies which could induce neuroprotection against cerebral ischemic injury. As for exendin-4, the data from several references have demonstrated that administration of exendin-4 before stroke resulted in neuroprotection (8,10,11,13). In our current study, mice received exendin-4 intranasally before MCAO injury and data showed that pretreatment with intranasal administration of exendin-4 exerted neuroprotective effect by reducing neurological deficit scores and infarct volume. These results indicated the potential use of exendin-4 for the treatment of stroke in type 2 diabetes patients or individuals at high risk to suffer from a stroke (e.g., pretreatment strategies).
Exendin-4 has been applied in clinic for the treatment of type 2 diabetes mellitus. However, the neuroprotective effect of exendin-4 against cerebral ischemia is gaining recognition. Our animal research indicated that the intranasal administration may be a more effective way to use exendin-4 against cerebral ischemia. Obviously, the application of our findings to human will need to be examined.
This work has been supported by three grants from the National Natural Science Foundation of China (81571278, 81471093, and 81201515).
COMPLIANCE WITH ETHICAL STANDARDS
Conflict of Interest
The authors declare that they have no competing interests.
- 5.Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750–8.CrossRefPubMedGoogle Scholar
- 6.Heppner KM, Kirigiti M, Secher A, Juel Paulsen S, Buckingham R, Pyke C et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2014:en20141675.Google Scholar